We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Global Hematology Testing Instrument Market Driven by Growing Demand for Preventive Diagnosis and Treatment Monitoring

By LabMedica International staff writers
Posted on 26 Aug 2021
Print article
Illustration
Illustration
The global hematology testing instrument market is witnessing high growth due to technological advances in disease diagnosis and rise in demand for preventive diagnosis and treatment monitoring.

These are the latest findings of Transparency Market Research (Albany, NY, USA), a next-generation market intelligence provider.

Hematology involves the study of blood, in particular how blood can affect overall health. Used in different settings, hematology instruments can do blood count, detect proteins or enzymes, and help to diagnose illnesses or genetic defects. Hematology tests can evaluate a number of blood conditions including infection, anemia, inflammation, hemophilia, blood-clotting disorders, leukemia, and the body’s response to chemotherapy treatments. Tests could be routine and regular, or these may be used to diagnose serious conditions in urgent situations.

Hematology testing devices have come a long way from disease detection and monitoring to counting and characterizing blood cells. The concept of automation has extended to detecting small cell populations to diagnose rare blood conditions, which require less labor, rapid result, and easy-to-use analyzers. Current technologies include automation of hematology analyzers, electrical impedance, flow cytometry, and fluorescent flow. The combination of these technologies has increased the yield and productivity of test results. Test volume i.e., number of tests performed, is projected to increase owing to technological advances in disease diagnosis and rise in demand for preventive diagnosis and treatment monitoring. This will also augment the demand for hematology analyzers with high throughput. Such technological revolutions in hematology testing are expected to propel the market growth during the forecast period.

However, technological advancements in blood testing instruments carry a heavy price tag. A number of laboratories cannot afford highly priced instruments. Therefore, there is a need of low-volume laboratory analyzers, which are cost-effective and easy-to-use. The high cost of instruments can increase testing cost, which can restrain the growth of the global hematology diagnostic market during the forecast period.

Geographically, North America is projected to dominate the global hematology diagnostic market during the forecast period. This can be attributed to the high average selling price of automated hematology analyzers, rise in demand among surgeons for technologically-advanced diagnostic instruments with enhanced specificity & precision, and favorable coverage as per the Clinical Laboratory Improvement Amendments for in-vitro diagnostic procedures in the region.

Related Links:
Transparency Market Research

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more